Athira Pharma, INC Schedule 13G passive stakes

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 7.7% beneficial ownership stake in LeonaBio, Inc.

Baslake Partners, LP, along with its management entity and managing member, reported a passive 1.9% beneficial ownership stake in LeonaBio, Inc. as of December 31, 2025.

Acorn Bioventures and its affiliates, including Anders Hove, have reported a combined beneficial ownership of 6.2% in Athira Pharma, Inc. common stock.

Acorn Bioventures and related entities, including Anders Hove, reported a combined beneficial ownership of 5.2% in Athira Pharma, Inc. common stock.

BML Investment Partners, L.P. and Leonard Braden Michael have reported a 0% beneficial ownership in Athira Pharma Inc.'s common stock.

Baslake Partners, along with Baselake Management and David Paolella, has reported a 5.0% passive ownership stake in Athira Pharma, Inc.

Steven Michael Oliveira and affiliated entities have reduced their beneficial ownership in Athira Pharma, Inc. to 4.088% of common stock.

Steven Michael Oliveira and affiliated entities Nemean Asset Management, LLC, South Ocean Capital Management LLC, and South Ocean Capital LLC have disclosed a combined passive beneficial ownership of 5.109% in Athira Pharma, Inc.'s common stock.

BML Investment Partners, L.P. and Leonard Braden Michael have filed an amended Schedule 13G, correcting their beneficial ownership of Athira Pharma Inc. common stock to 7.8% as of December 31, 2024.

BML Investment Partners, L.P. and Leonard Braden Michael have filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 6.5% of Athira Pharma Inc.'s common stock as of December 31, 2024.